Comparing Telehealth and In-Person Check-Ups for Glioma Patients on Oral Chemotherapy

Sponsor: Mayo Clinic

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT06625047

Provider View

This study is looking at how satisfied glioma patients are with telehealth versus in-person check-ups while they are taking oral chemotherapy. Gliomas are common brain cancers that can cause symptoms like tiredness and memory problems. The study aims to see if telehealth visits, which use technology to connect patients with doctors remotely, are as effective and preferred as in-person visits.

Patient Parameters

Program Overview

The study aims to compare how satisfied glioma patients are with telehealth check-ups versus in-person visits while they are on oral chemotherapy. Gliomas are a type of brain cancer that can cause symptoms like fatigue and memory issues. While care at specialized centers can improve survival, not all patients can easily access these centers due to physical or financial challenges. Telehealth uses technology to provide healthcare remotely, which might be more convenient for some patients. This study will help determine if telehealth is a good alternative to in-person visits for these patients.

Description

The main goal of this study is to see how satisfied patients are with their care, whether they have telehealth or in-person check-ups, by using a survey called the Press-Ganey survey.

Other goals include:

  • Checking if patients complete their planned oral chemotherapy within 28 days after telehealth visits compared to in-person visits.
  • Finding out if patients prefer telehealth or in-person check-ups.
  • Looking at how often patients need emergency care or hospital stays within 28 days after telehealth visits compared to in-person visits.
  • Measuring any changes in neurological symptoms using a scale called the NANO scale within 28 days after each type of visit.
  • Assessing quality of life using a questionnaire called the EORTC QLQ-C30 at the start and end of each chemotherapy cycle.

Patients will take a chemotherapy pill called temozolomide once a day for 5 days in a row, every 28 days, for up to 6 cycles, unless the disease gets worse or side effects are too severe. They will alternate between telehealth and in-person check-ups after each treatment cycle. After finishing the study treatment, patients will have a follow-up visit 30 days later.

Eligibility Criteria

Inclusion Criteria

  • Must be 18 years or older.
  • Have a diagnosis of glioma that requires additional chemotherapy. This includes glioblastoma, astrocytoma, and oligodendroglioma.
  • Eligible to receive temozolomide as part of standard care.
  • Have a performance status score indicating they are fully active or have some limitations but can still care for themselves.
  • Expected to live at least 6 more months according to their treatment team.
  • Willing and able to follow the study plan, including taking medication and attending scheduled visits.
  • Will be provided with a tablet for telehealth visits if they don't have one.
  • Will receive help with travel costs for in-person visits if needed.
  • Able to complete surveys about their experience, with or without help from a caregiver.

Exclusion Criteria

  • Have uncontrolled illnesses or conditions that make the study unsafe or difficult to follow.
  • Are pregnant, nursing, imprisoned, or unable to understand the study.
  • Cannot swallow tablets or have issues absorbing oral medication.
  • Have known allergies to temozolomide.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.